A randomized, single-center, double-blind, placebo-controlled, first-in-human trial with single and multiple ascending doses to determine safety, tolerability, and pharmacokinetics of GRT7040 in healthy volunteers
This is a very early study looking into a new medicine called GRT7040, which might one day help treat pain. Because it's the first time this medicine is being given to people, the main goals are to make sure it's safe to use, to see what side effects it might cause, and to understand how the body handles it. Healthy volunteers are taking part, receiving either GRT7040 or a dummy medicine (placebo), and the researchers will try out different dose amounts. This study is 'double-blind,' meaning neither the volunteers nor the study team know who is getting the real medicine. It's a key first step to see if GRT7040 could be a useful pain treatment in the future.
At a glance
What is this study about?
Imagine you have a new key, and you want to see if it works in a lock. This study is a bit like that, but with a new medicine called GRT7040. Researchers believe this medicine might help treat pain one day, but first, they need to make sure it's safe for people to take. This is the very first time GRT7040 will be given to human volunteers, which is why it's called a 'first-in-human' study.
The main aim here isn't to cure pain yet, but to carefully check a few important things. They want to find out if the medicine causes any serious side effects (this is called 'safety') and how well people can cope with it (this is called 'tolerability'). They also want to understand how the medicine behaves in the body – how much gets into the blood, how long it stays there, and how the body gets rid of it. This information is key to deciding if the medicine can be tested further in people who actually have pain.
In this study, some people will get the new medicine, and others will get a 'placebo,' which looks exactly like the medicine but contains no active ingredients. This helps researchers compare the effects accurately. Also, neither the volunteers nor the study doctors will know who is receiving which, so everyone's observations are unbiased. This is an essential first step in a long process of developing new medicines, laying the groundwork for future studies if GRT7040 proves to be safe and well-tolerated.
Key takeaways
- This is an early study (Phase I) of a new pain medicine called GRT7040.
- It's the first time GRT7040 is being given to people, specifically healthy volunteers.
- The main goals are to check for safety, side effects, and how the medicine works in the body.
- Participants will receive either the new medicine or a dummy pill (placebo).
- Neither volunteers nor staff will know who gets which ('double-blind').
- Your involvement helps pave the way for future pain treatments.
Who may be eligible?
To join this study, you need to be a healthy adult aged 18 or over. This means you generally don't have any major ongoing health problems and aren't taking lots of regular medication. Since it's a very early study with a new medicine, researchers like to test it in healthy people first to focus on the medicine's immediate effects without other health conditions making things complicated.
Both men and women are welcome to take part in this study. The researchers will have specific health checks to make sure you are suitable for the study. For example, they will look at your medical history and do some tests to make sure you are in good general health.
It's important that if you're interested, you share your full medical history with the study team. They will then be able to tell you if this study is the right fit for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you consider yourself generally healthy?
- Are you comfortable with the idea of taking a new, untested medicine (or a placebo)?
- Are you able to attend clinic visits and follow study instructions carefully?
- Are you willing to discuss your full medical history with the study team?
What does participation involve?
If you decide to take part, you would receive either the new medicine (GRT7040) or a placebo (a dummy medicine) by mouth. You would visit the study clinic for several appointments over a period of time. These visits would involve health checks, blood and urine tests, and careful monitoring for any side effects. You might stay overnight at the clinic for some of these visits. The study team would explain the exact number of visits, how long each might take, and what procedures would be involved. After receiving the medicine, there would be follow-up appointments to ensure you are well. The total time you would be involved in the study, from your first screening visit to your last follow-up, would be fully explained by the study team.
Potential risks and benefits
Locations (1)
- —UnverifiedGermany
Common questions
What does 'first-in-human' mean?
It means this is the very first time this new medicine is being given to people. It's a crucial early step in drug development.
Why is it being tested in healthy people first?
Testing in healthy people helps researchers understand the basic safety of the medicine and how the body handles it, without other health conditions getting in the way.
What is a 'placebo'?
A placebo is a dummy medicine that looks exactly like the real one but doesn't contain any active ingredients. It helps researchers compare effects.
What does 'double-blind' mean?
It means that neither you (the volunteer) nor the study team will know if you are getting the real medicine or the placebo. This helps keep the results unbiased.
Will this study help my pain now?
No, this study is not designed to treat pain. Its main goal is to check the safety and how the body handles the new medicine for future development.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.